Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States
Author:
Funder
American Cancer Society
Publisher
Elsevier BV
Subject
Urology
Reference24 articles.
1. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment;Gormley;J Urol,2015
2. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder;Siegel;Neurourol Urodyn,2015
3. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study);Tincello;Eur Urol,2012
4. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial;Chapple;Eur Urol,2013
5. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study;Denys;Eur Urol,2012
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-Term Cost Analysis of Third-Line Treatment Options for Overactive Bladder;Urology Practice;2024-01
2. National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019;Urology;2022-11
3. Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder;International Urogynecology Journal;2022-09-20
4. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA;PharmacoEconomics;2022-07-26
5. Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States;Journal of International Medical Research;2022-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3